TP53 and ovarian serous adenocarcinoma: In support of the prior studies, which found that low tau correlated with better overall and progression-free survival in patients with serous ovarian cancer [28], examination of survival data for patients with serous ovarian cancer bearing TP53 mutations in a Kaplan–Meier plotter database indicated that those with low tau expression survived 10 months longer than their counterparts with high tau expression (Figure 3C) [83].